Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTICCA-1
2024-517340-61-00Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial in cholangiocarcinoma (CCA) and gallbladder cancer comparing Gemcitabine + cisplatin with Capecitabine (2 arms). Primary endpoint: Disease free survival (DFS). Started Nov 2024; status: completed.
02
Drugs
gemcitabinecisplatincapecitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2024-517340-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517340-61-00.